As Nexavar’s Oncology Potential Grows, So Do Bayer’s Sales Predictions

Firm says the kidney cancer drug’s additional indications in liver cancer and potentially other cancers will raise peak sales beyond €500 million.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet